Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patien... View More